SMA patients with type 1 finally have access to Nusinersen/Spinraza in Canada

Mia

SMA patients with type 1 finally have access to Nusinersen/Spinraza in Canada

Biogen is offering coverage for SMA Patients with Type 2/3 have access to a special program , called Urgent Access Program. Cure SMA Canada celebrates a historic victory

Congratulation to Cure SMA Canada, well done 💪👋

Scholar Rock announced On Track to Initiate Phase 2 Proof-of-Concept Study in Later-Onset SMA in 1Q19

Scholar Rock made transformative progress in the second quarter with the successful completion of our IPO and the initiation of the Company’s first clinical trial,” said Nagesh Mahanthappa, Ph.D, President and CEO of Scholar Rock. “We are well-positioned to continue to progress SRK-015 and build our pipeline of future product… Att fortsätt läsa